Global Hormone Replacement Therapy Market is valued approximately USD 31.06billion in 2019 and is anticipated to grow with a healthy growth rate of more than 5.1 % over the forecast period 2020-2027. Hormone replacement therapy (HRT) is hormone replacement therapy for natural hormones when the body does not produce enough hormones. For instance, thyroid patients and human growth hormone patients take hormone replacement therapy. In addition, HRT has been widely administered to menopausal women for the relief of symptoms such as hot flushes, night sweats, sleep disturbances, psychological and genito-urinary problems, and for the prevention of osteoporosis. In addition, as per National Heart, Lung, and Blood the study of 2,000 American women, aged 30 to 60, found that in 2019, almost 47 percent of the population experienced the effects of a hormonal imbalance. Further, the key factors contributing to the growth of the global demand for hormone replacement therapy include growing the prevalence of menopausal disorders and rising consciousness among women about postmenopausal problems. Even as per NCBI in Nov 2020, approximately 1.3 million women undergo menopausal transition every year in the United States. It usually begins between the ages of 51 and 52. However, about 5% of women experience early menopause between the ages of 40 and 45. Furthermore, new hormone replacement therapy releases are projected to substantially contribute to the growth of the hormone replacement therapy industry. However, the high cost of treatment impedes the growth of the market over the forecast period of 2020-2027. Also, it is expected that the advent of bioidentical hormone replacement therapy and the use of telemedicine for hormone replacement therapy would provide a rewarding opportunity to broaden the global demand for hormone replacement therapy.

The regional analysis of global Hormone Replacement Therapy market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North American is the leading/significant region across the world in terms of market share owing to Increase in producers' releases of different generic hormone replacement therapy drugs, increase in target population and advances in drug delivery technologies, along with the production of new formulations. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as increased awareness of hormone replacement therapy, an unprecedented rise in the incidence of diabetes, and increased focus by healthcare providers in China, India, and Japan on reducing hormone deficiencies would create lucrative growth prospects for the Hormone Replacement Therapy market across Asia-Pacific region.

Major market player included in this report are:
Abbott Laboratories
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
Merck KGaA
Mylan N.V. (Viatris Inc.)
Novartis International AG
Novo Nordisk A/S
Pfizer Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapy Type:
Estrogen Hormone Replacement Therapy
Human Growth Hormone Replacement Therapy
Thyroid Hormone Replacement Therapy
Testosterone Hormone Replacement Therapy
Progestogen Hormone Replacement Therapy
By Route of Administration:
Oral
Parenteral
Others
By Indication:
Menopause
Hypothyroidism
Male Hypogonadism
Growth Hormone Deficiency
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of the Global Hormone Replacement Therapy Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors